title: [Blood conservation approaches in orthopedic surgery].
abstract: In addition to more restrictive "transfusion triggers", presently available allogeneic blood conservation strategies in surgery include preoperative increase in red blood cells (RBC) mass, techniques or pharmaceutical agents that reduce blood loss, and perioperative blood salvage. Because of very important risk reduction in allogeneic blood, benefit/risk of preautologous blood donation (PAD) is quite questionable at this moment. Indeed, at this moment in France, we focus to avoid any transfusion (allogeneic and autologous blood). Therefore the most important techniques used are pharmacological: erythropoietin before surgery with a number of injections related to baseline Hb, and tranexamic acid during and after surgery. Cell saving is used only if bleeding is enough important like arthroplasty revisions. All blood conservation techniques carry their own efficiency limits, constraints and risks that, in addition to institutional considerations and individual patient characteristics are determinant to settle a blood conservation strategy. The choice of a technique should take into account (a) the delay before surgery, (b) the anticipated blood loss for the procedure that varies among institutions, (c) the tolerable blood loss without transfusion for the patient, and (d) the efficacy of the blood conservation technique in the given setting. Nevertheless, at this moment in France, it is quite important to notice that the risk of delay or lack of transfusion induces much more deaths that the transfusion itself during or after anesthesia [Anesthesiology 105, 1087-97].
authors.affiliation: Service d'anesthésie-réanimation chirurgicale, hôpital Cochin, AP-HP, Paris, France. nadia.rosencher@cch.aphp.fr
authors.forename: N
authors.initials: N
authors.lastname: Rosencher
authors.forename: L
authors.initials: L
authors.lastname: Bellamy
authors.forename: T
authors.initials: T
authors.lastname: Chabbouh
authors.forename: L
authors.initials: L
authors.lastname: Arnaout
authors.forename: Y
authors.initials: Y
authors.lastname: Ozier
mesh_terms: D000740:Anemia / Q000097:blood / Q000517:prevention & control / Q000628:therapy; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D001804:Blood Transfusion, Autologous / Q000009:adverse effects; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use; D005290:Ferric Compounds / Q000494:pharmacology / Q000627:therapeutic use; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000097:blood; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000627:therapeutic use; D006438:Hemodilution; D006801:Humans; D007431:Intraoperative Complications / Q000209:etiology / Q000517:prevention & control; D019637:Orthopedic Procedures; D019106:Postoperative Hemorrhage / Q000517:prevention & control* / Q000628:therapy; D011300:Preoperative Care; D011994:Recombinant Proteins; D013395:Sucrose / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D065227:Transfusion Reaction
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D013395:Sucrose; D014148:Tranexamic Acid; D005293:Ferritins; D007611:Aprotinin; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid